IDH1 and central nervous system cancer: Consequently, we and others have shown in pre-clinical IDH mutant glioma models that mutant IDH or AHR inhibition via small molecule inhibitors has synergistic antitumoral effects when combined with immunotherapy such as ICI or vaccination [81–83].